Compare Stocks: MIRM, MRNA, INCY, and BNTX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BNTX BioNTech	$113.12 +22.0%	$92.48	$79.52 ▼ $124.00	$23.46B	1.27	932,430 shs	8.76 million shs
INCY Incyte	$128.47 +4.0%	$115.40	$81.09 ▼ $132.60	$25.03B	0.76	1.84 million shs	1.59 million shs
MIRM Mirum Pharmaceuticals	$102.24 +1.4%	$111.31	$63.23 ▼ $130.00	$6.55B	0.52	756,210 shs	556,260 shs
MRNA Moderna	$174.38 +177.0%	$64.91	$22.28 ▼ $176.66	$25.14B	0.91	5.37 million shs	194.97 million shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BNTX BioNTech	+21.96%	+21.98%	+22.74%	+24.40%	+1.54%
INCY Incyte	+4.05%	+6.38%	+11.09%	+31.89%	+50.33%
MIRM Mirum Pharmaceuticals	+1.36%	+3.30%	-12.33%	+1.56%	+56.91%
MRNA Moderna	+176.97%	+173.88%	+193.12%	+268.98%	+524.79%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BNTX BioNTech	$113.12 +22.0%	$92.48	$79.52 ▼ $124.00	$23.46B	1.27	932,430 shs	8.76 million shs
INCY Incyte	$128.47 +4.0%	$115.40	$81.09 ▼ $132.60	$25.03B	0.76	1.84 million shs	1.59 million shs
MIRM Mirum Pharmaceuticals	$102.24 +1.4%	$111.31	$63.23 ▼ $130.00	$6.55B	0.52	756,210 shs	556,260 shs
MRNA Moderna	$174.38 +177.0%	$64.91	$22.28 ▼ $176.66	$25.14B	0.91	5.37 million shs	194.97 million shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BNTX BioNTech	+21.96%	+21.98%	+22.74%	+24.40%	+1.54%
INCY Incyte	+4.05%	+6.38%	+11.09%	+31.89%	+50.33%
MIRM Mirum Pharmaceuticals	+1.36%	+3.30%	-12.33%	+1.56%	+56.91%
MRNA Moderna	+176.97%	+173.88%	+193.12%	+268.98%	+524.79%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BNTX BioNTech	2.74	Moderate Buy	$127.81	12.99% Upside
INCY Incyte	2.43	Hold	$121.65	-5.31% Downside
MIRM Mirum Pharmaceuticals	2.93	Moderate Buy	$137.33	34.32% Upside
MRNA Moderna	2.05	Hold	$56.56	-67.56% Downside

Current Analyst Ratings Breakdown

Latest MIRM, MRNA, INCY, and BNTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/19/2026	MRNA Moderna	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral
8/19/2026	MRNA Moderna	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral	$120.00
8/19/2026	MRNA Moderna	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sector Perform	$130.00
8/19/2026	MRNA Moderna	Loop Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$135.00
8/19/2026	MRNA Moderna	Brookline Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/19/2026	MRNA Moderna	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold
8/19/2026	MRNA Moderna	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Underperform ➝ Neutral
8/19/2026	MRNA Moderna	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform
8/17/2026	INCY Incyte	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$110.00 ➝ $130.00
8/13/2026	INCY Incyte	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Perform	$104.00
8/6/2026	MIRM Mirum Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D-) ➝ Sell (D)

(Data available from 8/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BNTX BioNTech	$3.25B	8.81	$1.63 per share	69.47	$81.64 per share	1.39
INCY Incyte	$5.14B	5.07	$6.43 per share	19.98	$31.30 per share	4.10
MIRM Mirum Pharmaceuticals	$521.31M	12.73	$0.05 per share	1,978.65	($0.16) per share	-639.00
MRNA Moderna	$1.94B	35.81	N/A	N/A	$16.93 per share	10.30

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BNTX BioNTech	-$1.29B	-$7.83	N/A	N/A	N/A	-63.54%	-6.86%	-6.00%	11/3/2026 (Estimated)
INCY Incyte	$1.29B	$7.85	16.37	15.94	3.91	27.71%	29.93%	22.88%	10/27/2026 (Estimated)
MIRM Mirum Pharmaceuticals	-$23.36M	-$14.55	N/A	N/A	N/A	-139.18%	-36.28%	-8.54%	11/3/2026 (Estimated)
MRNA Moderna	-$2.82B	-$7.99	N/A	N/A	N/A	-141.43%	-28.30%	-19.39%	11/5/2026 (Estimated)

Latest MIRM, MRNA, INCY, and BNTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2026	Q2 2026	MIRM Mirum Pharmaceuticals	-$0.7425	-$1.06	-$0.3175	-$1.06	$166.33 million	$176.24 million
8/4/2026	Q2 2026	BNTX BioNTech	-$2.3983	-$2.5340	-$0.1357	-$3.70	$180.18 million	$166.40 million
7/31/2026	Q2 2026	MRNA Moderna	-$2.03	-$1.97	+$0.06	-$1.97	$102.93 million	$145.00 million
7/28/2026	Q2 2026	INCY Incyte	$2.15	$3.09	+$0.94	$2.81	$1.50 billion	$1.67 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BNTX BioNTech	N/A	N/A	N/A	N/A	N/A
INCY Incyte	N/A	N/A	N/A	N/A	N/A
MIRM Mirum Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MRNA Moderna	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BNTX BioNTech	0.01	7.85	7.80
INCY Incyte	N/A	4.59	4.51
MIRM Mirum Pharmaceuticals	1.28	2.86	2.74
MRNA Moderna	0.09	2.29	2.18

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BNTX BioNTech	15.52%
INCY Incyte	96.97%
MIRM Mirum Pharmaceuticals	N/A
MRNA Moderna	75.33%

Insider Ownership

Company	Insider Ownership
BNTX BioNTech	19.20%
INCY Incyte	16.20%
MIRM Mirum Pharmaceuticals	8.32%
MRNA Moderna	10.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BNTX BioNTech	7,807	252.88 million	204.33 million	Optionable
INCY Incyte	2,844	202.70 million	169.86 million	Optionable
MIRM Mirum Pharmaceuticals	140	64.93 million	59.53 million	Optionable
MRNA Moderna	4,700	399.24 million	356.12 million	Optionable

MIRM, MRNA, INCY, and BNTX Headlines

Recent News About These Companies

Elon Musk Says mRNA Has 'Tremendous Promise,' Turning Disease Into a 'Software Problem,' as Moderna Stock Rockets 177% on Cancer Vaccine Breakthrough

43 minutes ago | finance.yahoo.com

E Fund Management Co. Ltd. Makes New Investment in Moderna, Inc. $MRNA

2 hours ago | marketbeat.com

Edmond DE Rothschild Holding S.A. Takes Position in Moderna, Inc. $MRNA

2 hours ago | marketbeat.com

5,814 Shares in Moderna, Inc. $MRNA Acquired by Commerzbank Aktiengesellschaft FI

2 hours ago | marketbeat.com

BlackRock Inc. Makes New Investment in Moderna, Inc. $MRNA

3 hours ago | marketbeat.com

Why Moderna Stock Skyrocketed Today

August 19 at 8:07 PM | fool.com

Moderna (MRNA)’s Melanoma Vaccine Win: Big Opportunity, Bigger Expectations

August 19 at 7:30 PM | insidermonkey.com

Merck, Moderna Cancer Vaccine Breakthrough Could Be Catalyst the mRNA ETF Trade Has Been Waiting For

August 19 at 5:49 PM | benzinga.com

Opinion | Moderna's Road to a Cancer Vaccine

August 19 at 5:45 PM | wsj.com

SLS Stock Edges Higher As Wall Street, Retail Expect Another MRNA Moment

August 19 at 5:37 PM | stocktwits.comS

Merck (MRK) Stock Trades Up, Here Is Why

August 19 at 5:37 PM | finance.yahoo.com

BioNTech Stock Surges 20% on Moderna Cancer Vaccine Win. Why the Gains Could Fade.

August 19 at 5:37 PM | finance.yahoo.com

Moderna, Merck melanoma cancer vaccine is a 'grand slam': Dr. Ezekiel Emanuel

August 19 at 5:37 PM | finance.yahoo.com

Moderna or Merck: Which Soaring Cancer Vaccine Stock Is the Better Buy?

August 19 at 5:36 PM | zacks.com

Moderna, Merck breakthrough could usher in wave of cancer vaccines

August 19 at 4:58 PM | reuters.com

U.S. Stocks Gain as Treasury Buybacks Calm Bond Yields; Moderna Surges

August 19 at 4:28 PM | wsj.com

Value Stocks Worth Watching - August 19th

August 19 at 3:01 PM | marketbeat.com

Technology Stocks To Follow Today - August 19th

August 19 at 3:00 PM | marketbeat.com

Moderna's Cancer Breakthrough Just Made Tempus AI's $1.5 Billion Bet Look Brilliant

August 19 at 2:44 PM | 247wallst.com

Moderna (NASDAQ:MRNA) Raised to "Neutral" at Bank of America

August 19 at 2:05 PM | marketbeat.com

$1,000 invested in Moderna stock a week ago is now worth

August 19 at 1:45 PM | finbold.comF

New MarketBeat Followers Over Time

Media Sentiment Over Time

MIRM, MRNA, INCY, and BNTX Company Descriptions

BioNTech NASDAQ:BNTX

$113.12 +20.37 (+21.96%)

Closing price 08/19/2026 04:00 PM Eastern

Extended Trading

$111.37 -1.75 (-1.55%)

As of 06:38 AM Eastern

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

Incyte NASDAQ:INCY

$128.47 +5.00 (+4.05%)

Closing price 08/19/2026 04:00 PM Eastern

Extended Trading

$129.00 +0.53 (+0.41%)

As of 06:37 AM Eastern

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Mirum Pharmaceuticals NASDAQ:MIRM

$102.24 +1.37 (+1.36%)

Closing price 08/19/2026 04:00 PM Eastern

Extended Trading

$102.50 +0.26 (+0.25%)

As of 06:30 AM Eastern

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.

Moderna NASDAQ:MRNA

$174.38 +111.42 (+176.97%)

Closing price 08/19/2026 04:00 PM Eastern

Extended Trading

$158.42 -15.97 (-9.16%)

As of 06:39 AM Eastern

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MIRM, MRNA, INCY, and BNTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MIRM, MRNA, INCY, and BNTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MIRM, MRNA, INCY, and BNTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

MIRM, MRNA, INCY, and BNTX Company Descriptions

BioNTech NASDAQ:BNTX

Incyte NASDAQ:INCY

Mirum Pharmaceuticals NASDAQ:MIRM

Moderna NASDAQ:MRNA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MIRM, MRNA, INCY, and BNTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MIRM, MRNA, INCY, and BNTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MIRM, MRNA, INCY, and BNTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

MIRM, MRNA, INCY, and BNTX Company Descriptions

BioNTech NASDAQ:BNTX

Incyte NASDAQ:INCY

Mirum Pharmaceuticals NASDAQ:MIRM

Moderna NASDAQ:MRNA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools